« Pfizer Tears It All Down |
| The Price of Publishing »
March 29, 2013
Sirtuins Live On at GSK
Well, GSK is shutting down the Sirtris operation in Cambridge, but sirtuins apparently live on. I'm told that the company is advertising for chemists and biologists to come to Pennsylvania to staff the effort, and in this market, they'll have plenty of takers. We'll have the sirtuin drug development saga with us for a while yet. And I'm glad, actually, and no, not just because it gives me something to write about. I'd like to know what sirtuins actually are capable of doing in humans, and I'd like to see a drug or two come out of this. What the odds of that are, though, I couldn't say. . .
+ TrackBacks (0) | Category: Drug Development
POST A COMMENT
- RELATED ENTRIES
- Postdoctoral Life (AKA What Shortage?)
- Fast Flow For DARPA
- Science Gifts 2014: Books on Drug Discovery and Medicinal Chemistry
- Whatever Happened to the Fish and the Frogs?
- Kickbacks At Sanofi?
- How Are Those Megamergers Working Out?
- GSK Cuts
- Puma and Neratinib Take Longer Than Expected